Company intelligence / Profile preview

Clementia Pharmaceuticals Inc.

Montreal, Quebec, Canada

Ownership: Private
Development stage: Commercial

Overview

Clementia was developing palovarotene, a novel RARγ agonist, for the treatment of FOP. The company was preparing for a 2019 NDA submission to the FDA. The Phase 3 MOVE Trial was evaluating an additional dosing regimen of palovarotene. Palovarotene was also in a Phase 2 trial (MO-Ped Trial) for multiple osteochondromas. The company was acquired by Ipsen in April 2019.

Therapeutic areas: OphthalmologyRare Diseases
Modalities: Small moleculesRARγ agonists
Industry: Biotech

Drug pipeline

1 asset

palovarotene

Commercial

Indications: Fibrodysplasia ossificans progressiva (FOP), Multiple osteochondromas (MO), Dry eye disease

Beyond the preview

Go deeper on Clementia Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clementia Pharmaceuticals Inc..

Explore the full profile